Loading...
  • leukemia
  • BACKGROUND AND OBJECTIVES: Leukemia relapse occurring in donor cells after allogeneic hematopoietic stem cell transplantation has been reported in rare cases. (haematologica.org)
  • The aim of this study was to demonstrate that extensive molecular characterization of leukemic cells at diagnosis and relapse may be necessary to avoid many technical pitfalls possibly leading to an erroneous diagnosis of leukemia relapse in donor cells after allogeneic transplantation. (haematologica.org)
  • After having achieved complete hematologic and molecular remission, two years later an overt leukemia relapse occurred with cytogenetic findings suggesting a leukemia relapse in donor cells. (haematologica.org)
  • INTERPRETATION AND CONCLUSIONS: While the simplest interpretation of the apparent female karyotype at relapse is the consequence of a loss of the Y chromosome which in leukemic blasts took place along with duplication of an X-chromosome, this case strongly emphasizes the need for accurate and extensive molecular characterization to prove the donor origin of a leukemia relapse after allogeneic transplantation. (haematologica.org)
  • Transfusion of donor CD8 + lymphocytes modified with transgenic MiHA-specific TCR is one of the promising methods of posttransplant leukemia therapy and relapse prophylaxis. (springer.com)
  • Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. (springer.com)
  • In an article published in the Journal of Clinical Oncology, Sharman et al provided long-term findings of a phase III trial that examined the addition of idelalisib to rituximab in relapsed chronic lymphocytic leukemia (CLL), including findings from an extension phase of idelalisib monotherapy. (ascopost.com)
  • Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience. (semanticscholar.org)
  • Although chronic myeloid leukemia (CML) was recognized as a distinct form of leukemia in the first half of the 19th century, it was not until advances in technology for characterizing human chromosomes in the late 1950s led to the discovery in 1960 that the leukemia cells harbored a consistent abnormality that came to be known as the Philadelphia (Ph 1 or now Ph) chromosome. (bloodjournal.org)
  • But unlike myeloid leukemia, B cell leukemia and lymphoma are less sensitive to allogeneic adoptive immunotherapy. (biomedcentral.com)
  • Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia. (amedeo.com)
  • Adult T-cell leukemia-lymphoma. (amedeo.com)
  • Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types. (amedeo.com)
  • cytogenetic
  • Complete cytogenetic and molecular response was achieved after allogeneic SCT followed by dasatinib treatment. (hindawi.com)
  • After the transplantation, although the complete cytogenetic response was achieved, there was no molecular response. (hindawi.com)
  • For CML, relapse will be defined as any cytogenetic evidence of a Philadelphia chromosome or persistence of BCR/ABL rearrangements by molecular testing on at least two measurements over a 6 month interval. (knowcancer.com)
  • mortality
  • In the past, several improvements including donor selection, immunosuppression and supportive care have been made to reduce non-relapse mortality. (springer.com)
  • Results The non-relapse mortality rate was 8% at 100 days and 15% at 1 year. (haematologica.org)
  • Results: With a median follow-up for alive patients of 56 (26-73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC. (icr.ac.uk)
  • diagnosis and relapse
  • However, the molecular cloning and sequencing of the CDRIII region of the immunoglobuin heavy chain (IgH) gene rearrangement in leukemic blasts at diagnosis and relapse demonstrated their identity thus formally proving the patient origin of both leukemic clones. (haematologica.org)
  • immune
  • The principles of treatment in this challenging situation are to reduce the disease burden on the one hand and to induce an allogeneic immune reaction on the other hand to achieve long-term disease control. (springer.com)
  • The graft-derived donor lymphocytes are capable of eliminating the residual recipient malignant cells in the course of allogeneic immune response, thus decreasing the chances of a relapse of the disease. (springer.com)
  • The anti-CD20 x anti-CD3 trifunctional bispecific antibody (trAb) FBTA05 may improve the targeting of tumor cells by redirecting immune allogeneic effector cells while reducing the risk of undesirable reactivity against normal host cells. (biomedcentral.com)
  • bone
  • Relapse without bone marrow involvement is much rarer. (hindawi.com)
  • Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts. (semanticscholar.org)
  • For non-CML, relapse will be defined based on disease specific morphologic criteria from a bone marrow biopsy and aspirate or recurrence of disease specific cytogenetics. (knowcancer.com)
  • rituximab
  • Based on this underlying treatment concept and on promising data taken from preclinical results and a small pilot study, an open-label, non-randomized, uncontrolled, dose-escalating phase I/II-study is conducted to evaluate safety and preliminary efficacy of the investigational antibody FBTA05 in combination with DLI for patients suffering from rituximab- and/or alemtuzumab-refractory, CD20-positive low- or high-grade lymphoma after allogeneic SCT. (biomedcentral.com)